dc.contributor.author | Dalgard, Olav | |
dc.contributor.author | Weiland, Ola | |
dc.contributor.author | Noraberg, Geir | |
dc.contributor.author | Karlsen, Lars Normann | |
dc.contributor.author | Heggelund, Lars | |
dc.contributor.author | Färkkilä, Martti | |
dc.contributor.author | Balselv, Ulla | |
dc.contributor.author | Berlard, Erika | |
dc.contributor.author | Øvrehus, Anne | |
dc.contributor.author | Kjær, Mette Skalshøi | |
dc.contributor.author | Krarup, Henrik | |
dc.contributor.author | Røge, Birgit Thorup | |
dc.contributor.author | Hallager, Sofie | |
dc.contributor.author | Madsen, Lone G | |
dc.contributor.author | Laursen, Alex Lund | |
dc.contributor.author | Lagging, Martin | |
dc.contributor.author | Weis, Nina | |
dc.date.accessioned | 2019-07-12T07:22:28Z | |
dc.date.available | 2019-07-12T07:22:28Z | |
dc.date.issued | 2017-07-13 | |
dc.identifier.citation | Dalgard, O., Weiland, O., Noraberg, G., Karlsen, L., Heggelund, L., Färkkilâ, M., ... & Krarup, H. (2017). Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections—a Scandinavian real-life study. PloS one, 12(7), e0179764. | en |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | https://hdl.handle.net/10642/7274 | |
dc.description.abstract | Background and aims
Chronic hepatitis C virus (HCV) genotype 3 infection with advanced liver disease has emerged as the most challenging to treat. We retrospectively assessed the treatment outcome of sofosbuvir (SOF) based regimes for treatment of HCV genotype 3 infections in a real life setting in Scandinavia.
Methods
Consecutive patients with chronic HCV genotype 3 infection were enrolled at 16 treatment centers in Denmark, Sweden, Norway and Finland. Patients who had received a SOF containing regimen were included. The fibrosis stage was evaluated by liver biopsy or transient liver elastography. The following treatments were given according availability and local guidelines: 1) SOF + ribavirin (RBV) for 24 weeks, 2) SOF + daclatasvir (DCV) +/-RBV for 12–24 weeks, 3) SOF + pegylated interferon alpha (peg-IFN-α) + RBV for 12 weeks or 4) SOF/ledipasvir (LDV) + RBV for 12–16 weeks. The primary endpoint was sustained virological response (SVR) assessed at week 12 (SVR12) after end of treatment.
Results
We included 316 patients with a mean age of 55 years (range 24–79), 70% men, 49% treatment experienced, 58% with compensated cirrhosis and 12% with decompensated cirrhosis.In the modified intention to treat (mITT) population SVR12 was achieved in 284/311 (91%) patients. Among 26 treatment failures, five had non-response, 3 breakthrough and 18 relapse. Five patients were not included in the mITT population. Three patients died from reasons unrelated to treatment and two were lost to follow-up. The SVR12 rate was similar for all treatment regimens, but lower in men (p = 0.042), and in patients with decompensated liver disease (p = 0.004).
Conclusion
We found that sofosbuvir based treatment in a real-life setting could offer SVR rates exceeding 90% in patients with HCV genotype 3 infection and advanced liver disease. | en |
dc.language.iso | en | en |
dc.publisher | PLOS | en |
dc.relation.ispartofseries | PLoS ONE;12(7) | |
dc.rights | Attribution 3.0 United States
This is an open access article originally published at https://doi.org/10.1371/journal.pone.0179764 | en |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.subject | VDP::Medisinske Fag: 700 | en |
dc.subject | Artikkel | en |
dc.title | Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections - a Scandinavian real-life study | en |
dc.type | Journal article | en |
dc.type | Peer reviewed | en |
dc.description.version | publishedVersion | en |
dc.identifier.doi | https://doi.org/10.1371/journal.pone.0179764 | |
dc.identifier.cristin | 1502641 | |